Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies

Journal of Clinical Oncology

Volumn 29, Issue 13, 2011, Pages 1757-1764

  Hurwitz, Herbert I ^a,b,c,d,e,f   Saltz, Leonard B ^a,b,c,d,e,f   Van Cutsem, Eric ^a,b,c,d,e,f   Cassidy, James ^a,b,c,d,e,f   Wiedemann, Jonas ^a,b,c,d,e,f   Sirzén, Florin ^a,b,c,d,e,f   Lyman, Gary H ^a,b,c,d,e,f   Rohr, Ulrich Peter ^a,b,c,d,e,f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PACLITAXEL; PLACEBO; RECOMBINANT ALPHA2A INTERFERON;

ADD ON THERAPY; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; PANCREAS CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TUMOR CLASSIFICATION; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS THROMBOEMBOLISM;

EID: 79955587689     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.3220     Document Type: Article

References (35)

1. Lyman GH, Khorana AA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007 (Pubitemid 350232226)
2. Lyman GH, Khorana AA: Cancer, clots and consensus: New understanding of an old problem. J Clin Oncol 27:4821-4826, 2009
3. Levine MN, Lee AY, Kakkar AK: From Trousseau to targeted therapy: New insights and innovations in thrombosis and cancer. J Thromb Haemost 1:1456-1463, 2003
4. Elice F, Jacoub J, Rickles FR, et al: Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 83:862-870, 2008
5. Lip GY, Chin BS, Blann AD: Cancer and the prothrombotic state. Lancet Oncol 3:27-34, 2002 (Pubitemid 34121143)
6. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 6: 401-410, 2005 (Pubitemid 40753746)
7. Otten HM, Mathijssen J, ten Cate H, et al: Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: An underestimated phenomenon. Arch Intern Med 164:190-194, 2004 (Pubitemid 38140406)
8. Wun T, White RH: Venous thromboembolism (VTE) in patients with cancer: Epidemiology and risk factors. Cancer Invest 27:63-74, 2009 (suppl 1)
9. Khorana AA, Connolly GC: Assessing risk of venous thromboembolism in patients with cancer. J Clin Oncol 27:4839-4847, 2009
10. Nalluri SR, Chu D, Keresztes R, et al: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A metaanalysis. JAMA 300:2277-2285, 2008
11. Minor DR: Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA 301: 1434, 2009
12. Kilickap S, Arslan C: Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA 301:1435, 2009
13. Cortes J, Saura C, Atzori F: Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA 301:1434-1435, 2009
14. Scappaticci FA, Skillings JR, Holden SN, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239, 2007 (Pubitemid 47299901)
15. Ranpura V, Hapani S, Chuang J, et al: Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol 49:287-297, 2010
16. Azzi GR, Schutz FA, Je Y, et al. Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients. J Clin Oncol 28:369s, 2010 (suppl; abstr 4609)
17. Full prescribing information for bevacizumab. http://www.gene.com/gene/ products/information/pdf/avastin-prescribing.pdf
18. Mackman N: Triggers, targets and treatments for thrombosis. Nature 451:914-918, 2008
19. Franchini M, Mannucci PM: Venous and arterial thrombosis: Different sides of the same coin? Eur J Intern Med 19:476-481, 2008
20. Lyman GH, Kuderer NM: The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 5:14, 2005
21. Stewart LA, Parmar MK: Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 341:418-422, 1993
22. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004 (Pubitemid 41095154)
23. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
24. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005
25. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
26. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
27. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27:1227-1234, 2009
28. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, doubleblind phase III trial. Lancet 370:2103-2111, 2007 (Pubitemid 350296300)
29. Van Cutsem E, Vervenne WL, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237, 2009
30. Miles D, Chan A, Romieu G, et al: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26;43s, 2008 (suppl; abstr LBA1011)
31. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
32. Calvo V, Ramirez N, Saura C, et al: Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. J Clin Oncol 28: 124s, 2010 (suppl; abstr 1043)
33. Kang Y, Ohtsu A, Van Cutsem E, et al: AVAGAST: A randomized, double-blind, placebocontrolled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28:302s, 2010 (suppl; abstr LBA4007)
34. Leighl N, Bennouna J, Kuo H: Safety of bevacizumab treatment in non-small cell lung cancer (NSCLC) subjects receiving full-dose anti-coagulation (FDAC) treated on protocol BO17704. Eur J Cancer 391, 2007 (suppl 5; abstr 6610)
35. Van Cutsem E, Rivera F, Berry SR, et al: Exposure to anticoagulant medication in patients treated with bevacizumab: Subgroup analysis from the Bevacizumab Expanded Access Trial (BEAT). ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 (abstr 431)